Erica N Boswell

发表

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.

K. Anderson, P. Richardson, S. Rodig, 2013, Blood.

Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia

P. Richardson, P. Armand, S. Treon, 2015, Leukemia.

Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm.

H. Hatabu, I. Ghobrial, M. Nishino, 2015, The oncologist.

Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).

J. Laubach, P. Richardson, P. Armand, 2014 .

Phase I study of TH-302, an investigational hypoxia-targeted drug, and dexamethasone in patients with relapsed/refractory multiple myeloma.

J. Laubach, P. Richardson, P. Armand, 2013 .

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.

P. Richardson, S. Rodig, F. Azab, 2013, Blood.

CLINICAL TRIALS AND OBSERVATIONS Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia

P. Richardson, F. Azab, I. Ghobrial, 2017 .

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma

N. Munshi, J. Laubach, P. Richardson, 2010 .